Aarkstore - Type 2 Diabetes - Pipeline Review, H2 2014 - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore - Type 2 Diabetes - Pipeline Review, H2 2014 PowerPoint presentation | free to download - id: 72c409-ODg2M



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore - Type 2 Diabetes - Pipeline Review, H2 2014

Description:

Type 2 Diabetes - Pipeline Review, H2 2014 report reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects. Browse full report @ – PowerPoint PPT presentation

Number of Views:14

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Type 2 Diabetes - Pipeline Review, H2 2014


1
Type 2 Diabetes - Pipeline Review, H2 2014
Pharmaceutical and Healthcare Market Research
Report
2
Summary
  • Type 2 Diabetes - Pipeline Review, H2 2014,
    provides an overview of the Type 2 Diabetess
    therapeutic pipeline.
  • This report provides comprehensive information
    on the therapeutic development for Type 2
    Diabetes, complete with comparative analysis at
    various stages, therapeutics assessment by drug
    target, mechanism of action (MoA), route of
    administration (RoA) and molecule type, along
    with latest updates, and featured news and press
    releases. It also reviews key players involved in
    the therapeutic development for Type 2 Diabetes
    and special features on late-stage and
    discontinued projects.
  • Global Markets Directs report features
    investigational drugs from across globe covering
    over 20 therapy areas and nearly 3,000
    indications. The report is built using data and
    information sourced from Global Markets Directs
    proprietary databases, Company/University
    websites, SEC filings, investor presentations and
    featured press releases from company/university
    sites and industry-specific third party sources,
    put together by Global Markets Directs team.

3
Scope
  • - The report provides a snapshot of the global
    therapeutic landscape of Type 2 Diabetes- The
    report reviews key pipeline products under drug
    profile section which includes, product
    description, MoA and RD brief, licensing and
    collaboration details other developmental
    activities - The report reviews key players
    involved in the therapeutics development for Type
    2 Diabetes and enlists all their major and minor
    projects- The report summarizes all the dormant
    and discontinued pipeline projects - A review of
    the Type 2 Diabetes products under development by
    companies and universities/research institutes
    based on information derived from company and
    industry-specific sources- Pipeline products
    coverage based on various stages of development
    ranging from pre-registration till discovery and
    undisclosed stages- A detailed assessment of
    monotherapy and combination therapy pipeline
    projects- Coverage of the Type 2 Diabetes
    pipeline on the basis of target, MoA, route of
    administration and molecule type- Latest news
    and deals relating related to pipeline products

4
Reasons to buy
  • - Provides strategically significant competitor
    information, analysis, and insights to formulate
    effective RD development strategies- Identify
    emerging players with potentially strong product
    portfolio and create effective counter-strategies
    to gain competitive advantage- Develop strategic
    initiatives by understanding the focus areas of
    leading companies- Identify and understand
    important and diverse types of therapeutics under
    development for Type 2 Diabetes- Plan mergers
    and acquisitions effectively by identifying key
    players of the most promising pipeline- Devise
    corrective measures for pipeline projects by
    understanding Type 2 Diabetes pipeline depth and
    focus of Indication therapeutics- Develop and
    design in-licensing and out-licensing strategies
    by identifying prospective partners with the most
    attractive projects to enhance and expand
    business potential and Scope- Modify the
    therapeutic portfolio by identifying discontinued
    projects and understanding the factors that drove
    them from pipeline

5
Table of Content
  • Introduction 9Type 2 Diabetes Overview
    10Therapeutics Development 11Type 2 Diabetes -
    Therapeutics under Development by Companies
    13Type 2 Diabetes - Therapeutics under
    Investigation by Universities/Institutes 31Type
    2 Diabetes - Pipeline Products Glance 33Type 2
    Diabetes - Products under Development by
    Companies 37Type 2 Diabetes - Products under
    Investigation by Universities/Institutes 57Type
    2 Diabetes - Companies Involved in Therapeutics
    Development 60Type 2 Diabetes - Therapeutics
    Assessment 267Drug Profiles 293Type 2 Diabetes
    - Recent Pipeline Updates 986Type 2 Diabetes -
    Dormant Projects 1095Type 2 Diabetes -
    Discontinued Products 1106Type 2 Diabetes -
    Product Development Milestones 1111Appendix 1119

6
List of Tables
  • Number of Products under Development for Type 2
    Diabetes, H2 2014 69Number of Products under
    Development for Type 2 Diabetes - Comparative
    Analysis, H2 2014 70Number of Products under
    Development by Companies, H2 2014 72Number of
    Products under Development by Companies, H2 2014
    (Contd..1) 73Number of Products under
    Development by Companies, H2 2014 (Contd..2)
    74Number of Products under Development by
    Companies, H2 2014 (Contd..3) 75Number of
    Products under Development by Companies, H2 2014
    (Contd..4) 76Number of Products under
    Development by Companies, H2 2014 (Contd..5)
    77Number of Products under Development by
    Companies, H2 2014 (Contd..6) 78Number of
    Products under Development by Companies, H2 2014
    (Contd..7) 79Number of Products under
    Development by Companies, H2 2014 (Contd..8)
    80Number of Products under Development by
    Companies, H2 2014 (Contd..9) 81Number of
    Products under Development by Companies, H2 2014
    (Contd..10) 82Number of Products under
    Development by Companies, H2 2014 (Contd..11)
    83Number of Products under Development by
    Companies, H2 2014 (Contd..12) 84

7
List of Figures
  • Number of Products under Development for Type 2
    Diabetes, H2 2014 69Number of Products under
    Development for Type 2 Diabetes - Comparative
    Analysis, H2 2014 70Number of Products under
    Development by Companies, H2 2014 71Number of
    Products under Investigation by
    Universities/Institutes, H2 2014 89Comparative
    Analysis by Late Stage Development, H2 2014
    91Comparative Analysis by Clinical Stage
    Development, H2 2014 92Comparative Analysis by
    Early Stage Products, H2 2014 93Assessment by
    Monotherapy Products, H2 2014 325Assessment by
    Combination Products, H2 2014 326Number of
    Products by Top 10 Targets, H2 2014 327Number of
    Products by Stage and Top 10 Targets, H2 2014
    327Number of Products by Top 10 Mechanism of
    Actions, H2 2014 337Number of Products by Stage
    and Top 10 Mechanism of Actions, H2 2014
    337Number of Products by Top 10 Routes of
    Administration, H2 2014 347

8
List of Figures
  • Number of Products under Development for Type 2
    Diabetes, H2 2014 69Number of Products under
    Development for Type 2 Diabetes - Comparative
    Analysis, H2 2014 70Number of Products under
    Development by Companies, H2 2014 71Number of
    Products under Investigation by
    Universities/Institutes, H2 2014 89Comparative
    Analysis by Late Stage Development, H2 2014
    91Comparative Analysis by Clinical Stage
    Development, H2 2014 92Comparative Analysis by
    Early Stage Products, H2 2014 93Assessment by
    Monotherapy Products, H2 2014 325Assessment by
    Combination Products, H2 2014 326Number of
    Products by Top 10 Targets, H2 2014 327Number of
    Products by Stage and Top 10 Targets, H2 2014
    327Number of Products by Top 10 Mechanism of
    Actions, H2 2014 337Number of Products by Stage
    and Top 10 Mechanism of Actions, H2 2014
    337Number of Products by Top 10 Routes of
    Administration, H2 2014 347

9
Browse Full Report
  • Or Sample Request _at_
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/60599/type-2-diabetes-pipeline-review-h2-2014

10
Related Reports
  • Sinusitis-Pipeline Insights, 2015
  • Oligodendroglioma-Pipeline Insights, 2015
  • Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia)-Pipeline Insights, 2015
  • Fatty Liver Disease-Pipeline Insights, 2015
  • Skin And Skin Structure Infections by
    S.Pneumoniae-Pipeline Insights, 2015
  • Opioid-Induced Constipation (OIC)-Pipeline
    Insights, 2015
  • Female Infertility-Pipeline Insights, 2015
  • Optic Neuritis-Pipeline Insights, 2015

11
Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
12
Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
About PowerShow.com